1-异丙基-2-苯基-吖丁啶 | 156370-50-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 中文名称: 1-异丙基-2-苯基-吖丁啶
• 英文名称: N-isopropyl-2-phenylazetidine
• 英文别名: 1-Isopropyl-2-phenylazetidine；2-phenyl-1-propan-2-ylazetidine
• CAS: 156370-50-2
• 化学式: C₁₂H₁₇N
• 分子量: 175.274
• InChiKey: YEYFGCVSSYLSAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-异丙基-2-苯基-吖丁啶 在 4,4'-二叔丁基苯并 、 水 、 lithium 作用下， 生成 N-异丙基-3-苯基-1-丙胺
  参考文献：
  名称：

  4,4′-Di-tert-butylbiphenyl-catalysed reductive opening of azetidines with lithium: A direct preparation of 3,N-dilithioalkylamines

  摘要：

  The reaction of N-phenylazetidine 1a with an excess of lithium powder and a catalytic amount of 4,4'-ditert-butylbiphenyl (5 mol %) in THF at -15 degrees C leads to the corresponding dianion 2a, which by treatment with different electrophiles (H2O, D2O, Bu(CHO, PhCHO, (CH2)(5)CO, PhCH=NPh, CO2) yields, after hydrolysis with mater, the expected functionalysed amines 3aa-ah. The same method applied to N-isopropyl-2-phenylazetidine Ic affords compounds 3ca-ce (electrophiles: H2O, D2O, PhCHO, Me(2)CO, CH2=CHCH2Br) resulting from the more stable benzylic intermediate 2c. Finally, the regiochemistry in the reductive opening of 2-methyl-N-phenylazetidine Id followed by deuterolysis was studied: a mixture of both regioisomers 3da+3da' was obtained, the ratio being the oposite as expected according to the stability of both intermediates 2d and 2d'.

  DOI：

  10.1016/s0040-4020(01)85645-3
• 作为产物：
  描述：

  3-(isopropylamino)-1-phenyl-1-propanol 在 sodium hydroxide 、 氯化亚砜 作用下， 以 氯仿 为溶剂， 反应 74.5h， 生成 1-异丙基-2-苯基-吖丁啶
  参考文献：
  名称：

  4,4′-Di-tert-butylbiphenyl-catalysed reductive opening of azetidines with lithium: A direct preparation of 3,N-dilithioalkylamines

  摘要：

  The reaction of N-phenylazetidine 1a with an excess of lithium powder and a catalytic amount of 4,4'-ditert-butylbiphenyl (5 mol %) in THF at -15 degrees C leads to the corresponding dianion 2a, which by treatment with different electrophiles (H2O, D2O, Bu(CHO, PhCHO, (CH2)(5)CO, PhCH=NPh, CO2) yields, after hydrolysis with mater, the expected functionalysed amines 3aa-ah. The same method applied to N-isopropyl-2-phenylazetidine Ic affords compounds 3ca-ce (electrophiles: H2O, D2O, PhCHO, Me(2)CO, CH2=CHCH2Br) resulting from the more stable benzylic intermediate 2c. Finally, the regiochemistry in the reductive opening of 2-methyl-N-phenylazetidine Id followed by deuterolysis was studied: a mixture of both regioisomers 3da+3da' was obtained, the ratio being the oposite as expected according to the stability of both intermediates 2d and 2d'.

  DOI：

  10.1016/s0040-4020(01)85645-3

文献信息

• [EN] SUBSTITUTED PYRIDAZINONE FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES<br/>[FR] PYRIDAZINONE SUBSTITUÉE DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT DE MALADIES NEUROMUSCULAIRES
  申请人：EDGEWISE THERAPEUTICS INC

  公开号：WO2021231546A1

  公开（公告）日：2021-11-18

  Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-α.

  本文披露了用于治疗神经肌肉疾病，如杜兴氏肌肉萎缩症（DMD）的吡啶并嗪酮化合物、结合物和药物组合物。所披露的化合物在治疗DMD以及调节炎症抑制剂IL-1、IL-6或TNF-α等方面具有用途。
• SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS
  申请人：Andrews Steven W.

  公开号：US20110166122A1

  公开（公告）日：2011-07-07

  Compounds of Formula (I): in which R 1 , R 2 , R 3 , R 4 , X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor.

  式(I)的化合物：其中R1、R2、R3、R4、X、Y和n具有规范中给出的含义，是Trk激酶的抑制剂，可用于治疗可用Trk激酶抑制剂治疗的疾病。
• Substituted Pyrazolo[1,5-a]Pyrimidine Compounds as TRK Kinase Inhibitors
  申请人：Haas Julia

  公开号：US20110195948A1

  公开（公告）日：2011-08-11

  Compounds of Formula (I) in which R 1 , R 2 , R 3 , R 4 , X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor.

  式(I)的化合物中，其中R1、R2、R3、R4、X、Y和n的含义如规范中所述，是Trk激酶的抑制剂，可用于治疗可用Trk激酶抑制剂治疗的疾病。
• COMPOUNDS AND METHODS OF USE
  申请人：Baell Jonathan Bayldon

  公开号：US20120184541A1

  公开（公告）日：2012-07-19

  In one aspect, the present invention provides for a compound of Formula I in which in Formula I, the variables X 1 , X 2a , X 2b , X 2c , R 1 , B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-x L proteins.

  在一个方面，本发明提供了一种公式I的化合物，其中在公式I中，变量X1、X2a、X2b、X2c、R1、B、L、E、A和下标n的定义如本文所述。在另一个方面，本发明提供了包含公式I化合物的药物组合物，以及使用公式I化合物治疗通过表达或过度表达Bcl-2抗凋亡蛋白（例如抗凋亡Bcl-xL蛋白）的疾病和病况（例如癌症、血小板增多症等）的方法。
• SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
  申请人：Allen Shelley

  公开号：US20120108568A1

  公开（公告）日：2012-05-03

  Compounds of Formula (I) and salts thereof in which R 1 , R 2 , R 3 , R 4 , X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

  式(I)的化合物及其盐，其中R1、R2、R3、R4、X、Y和n的含义如规范中所述，是Trk激酶的抑制剂，可用于治疗可以用Trk激酶抑制剂治疗的疾病，例如疼痛、癌症、炎症、神经退行性疾病和某些传染病。